I lost money in CLSN and if some of the biotech investors here are honest, they will admit they lost money in CLSN. None of us want to go through another CLSN and this does look similar at least to big market movers, hence the lack of interest.
The similarity in CLSN and NWBO is that they have promising results from an unproven technology. The results look promising but are very preliminary and unproven and speculative by rigorous analysis.
The second common factor seems to Sabby management involvement in both.
The similarity ends there.
CLSN had shady management some of whom could not get a job anywhere. On investor Village board there was some talk and postings which seemed to imply the CFO had been involved in a previous stock scam. I don't know how true this is but the papers and records posted looked authentic and had the same name as the CFO (which is an uncommon name). Secondly a few days before the results came out they cancelled their presentations at some prominent meetings. Even now they are hyping some subsect of results so they can keep this charade going so they can continue to draw their salaries.
In the case of NWBO most of the money keeping it afloat comes from the CEOs other companies. If this goes bankrupt the person who loses most is Linda. She has spent enormous effort and time in keeping this alive; no reason to do so unless she profits from it. She is independently wealthy and probably doing it for the money and fame.
Secondly unlike CLSN they have other prestigious medical institutions supporting from Germany and UK. They have a grant from Germany. Unlikely all these places would all be fooled by a scam.
CLSN had only one set of preliminary results which were the basis for the trial. Looking back it seems odd because doxorubicin is not very effective for liver cancer and no one had been able to duplicate their results. In this case they have good results from CNS tumors but also some evidence in other tumors such as ovarian c